HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis

US6953858B2 · kind B2 · utility

Assignee

• Agouron Pharmaceuticals, Inc. · US

Inventors

• Stacie S. Canan Koch · Village of La Jolla, US
• Therese Alexander · San Diego, US
• Mark Barvian · Ann Arbor, US
• Gary L. Bolton · Ann Arbor, US
• Frederick Earl Boyer, Jr. · Canton, US
• Benjamin Joseph Burke · San Diego, US
• Tod Holler · Ann Arbor, US
• Tanya Michelle Jewell · Encinitas, US
• Vara Prasad Venkata Nagendra Josyula · Ann Arbor, US
• David Kucera · Del Mar, US
• Maria Angelica Linton · San Diego, US
• Jeffrey Machak · Shelby Charter Township, US
• Lennert J. Mitchell, Jr. · Chula Vista, US
• Sean Murphy · San Diego, US
• Siegfried H. Reich · San Diego, US
• Donald J. Skalitzky · San Diego, US
• John Howard Tatlock · San Diego, US
• Michael D. Varney · Carlsbad, US
• Scott C. Virgil · Pasadena, US
• Stephen E. Webber · San Diego, US
• Stephen Worland · Del Mar, US
• Michael Joseph Melnick · Portage, US

Key dates

• Filing date: Jun 11, 2002
• Grant date: Oct 11, 2005
• Expiry date: Jul 20, 2022

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D471/08
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds of the formula: where the formula variables are as defined herein, are disclosed that advantageously inhibit or block the biological activity of the HIV protease. These compounds, as well as pharmaceutical compositions containing these compounds, are useful for treating patients or hosts infected with the HIV virus. Intermediates and synthetic methods for preparing such compounds are also described.